A Promising Screening Tool for Prescription Opioid Use Disorders in Older Adults?

2016 ◽  
Vol 24 (8) ◽  
pp. 637-638
Author(s):  
Antoine Douaihy
F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 87 ◽  
Author(s):  
George E. Woody

The development of medications for treating persons with opioid use disorders has expanded the number of evidence-based treatment options, particularly for persons with the most severe disorders. It has also improved outcomes compared to psychosocial treatment alone and expanded treatment availability by increasing the number of physicians involved in treatment and the settings where patients can be treated. The medications include methadone, buprenorphine, buprenorphine/naloxone, and extended-release injectable naltrexone. Studies have shown that they are most effective when used over an extended, but as-yet-unspecified, period of time and with counseling and other services, particularly for the many with psychosocial problems. Though controversial in some cultures, well-designed studies in Switzerland, the Netherlands, Germany, and Canada have demonstrated the efficacy of supervised heroin injecting for persons who responded poorly to other treatments, and this treatment option has been approved by Switzerland and a few other E.U. countries. The degree to which medication-assisted therapies are available is dependent on many variables, including national and local regulations, preferences of individual providers and their geographical location, treatment costs, and insurance policies. Greater availability of medication-assisted therapies has become a major focus in the U.S. and Canada, where there has been a marked increase in deaths associated with heroin and prescription opioid use. This paper provides a brief summary of these developments.


2021 ◽  
Vol 36 (5) ◽  
pp. 388-395 ◽  
Author(s):  
Anthony V. Herrera ◽  
Linda Wastila ◽  
Jessica P. Brown ◽  
Hegang Chen ◽  
Steven R. Gambert ◽  
...  

2017 ◽  
Vol 6 (1) ◽  
pp. 73-84 ◽  
Author(s):  
Andrew J. M. Cooper ◽  
Jenna Willis ◽  
Janice Fuller ◽  
Heike Benecke ◽  
James Leighton-Scott ◽  
...  

2006 ◽  
Vol 55 (1) ◽  
pp. 35-41 ◽  
Author(s):  
Daniel H. Solomon ◽  
Jerry Avorn ◽  
Philip S. Wang ◽  
George Vaillant ◽  
Danielle Cabral ◽  
...  

2013 ◽  
Vol 131 (1-2) ◽  
pp. 143-148 ◽  
Author(s):  
Carlos Blanco ◽  
Miren Iza ◽  
Robert P. Schwartz ◽  
Claudia Rafful ◽  
Shuai Wang ◽  
...  

Pain Medicine ◽  
2020 ◽  
Vol 21 (11) ◽  
pp. 2757-2764
Author(s):  
Louisa Picco ◽  
Melissa Middleton ◽  
Raimondo Bruno ◽  
Michala Kowalski ◽  
Suzanne Nielsen

Abstract Objective The OWLS is a screening tool for prescription opioid use disorder designed for use in primary care. This study aimed to confirm the optimal wording, scoring methods, and cutoff for the OWLS. Design and Setting Cross-sectional analysis of an online sample. Subjects Participants comprised those with chronic noncancer pain who regularly used prescription opioids. Methods Eligible participants self-completed an online version of the OWLS prescription opioid use disorder screening tool and the Composite International Diagnostic Interview Substance Abuse module. Receiver operating characteristics were calculated for three scoring methods for the OWLS, and these were compared with DSM-5 classification of any use disorder and moderate to severe opioid use disorder. Results Among the sample (N = 324), utilizing scoring method (i) (i.e., positive endorsement ≥ response option “a little bit”) and a cutoff of 3 increased the percentage of correctly classified participants, with concurrent increases in specificity and decreases in false discovery rate, and false positive rate. Conclusion OWLS utilizing scoring method (i) with a cutoff of 3 was shown to be the optimal version and scoring method of this tool. This represents a time-efficient, simple scoring method, allowing for quick and accurate screening for opioid use disorder to occur.


Sign in / Sign up

Export Citation Format

Share Document